Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruitment Status: Recruiting
Start Date: May 01, 2008
Inclusion Criteria:
- The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy;or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1
- Hodgkin lymphoma
- CCG 5942
- POG 9425
- POG 9426
- AHOD0031
- AHOD1331
- S1826 (COG patients only)
- Brain tumor
- A9961
- Acute lymphoblastic leukemia
- POG 9404
- Osteosarcoma
- POG 9754
- Stem cell transplantation
- ASCT0631D
- Rhabdomyosarcoma
- IRS-III
- IRS-IV
- Late Effects Protocols with Patients Eligible for Enrollment on ALTE05N1
- ALTE15N1
- ALTE16C1
- Enrollment on ALTE05N1 must occur within 24 calendar months of the date the patient was enrolled on a frontline COG therapeutic trial; or patients previously enrolled on a COG (or Legacy Group) trial targeted for long term follow-up by ALTE05N1 may enroll on ALTE05N1 at any time
- The patient must reside in the U.S. on the date of enrollment to ALTE05N1
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met